Rennie®
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Renny - antacid.
Pharmacodynamics
Antacid preparation of local action. Tablet renny® contains antacid substances - calcium carbonate and magnesium carbonate, which provide fast and long-lasting neutralization of excess hydrochloric acid of the gastric juice, thereby providing a protective effect on the gastric mucosa. Achieving a positive effect within 3-5 minutes is due to the good solubility of pills and high calcium content.
Pharmacokinetics
As a result of the interaction Renny® with the gastric juice in the stomach soluble salts of calcium and magnesium are formed.
The degree of absorption of calcium and magnesium from these compounds depends on the dose of the drug. Maximum absorption is 10% calcium and 15–20% magnesium. A small amount of absorbed calcium and magnesium is excreted through the kidneys. In case of impaired renal function, the concentration of calcium and magnesium in the plasma may increase. In the intestine of soluble salts are formed insoluble compounds that are excreted in the feces.
Indications
Symptoms associated with increased acidity of gastric juice and reflux esophagitis (including caused by inaccuracy in the diet, medication, alcohol abuse, coffee, nicotine):
- heartburn;
- sour belching;
- recurrent pain in the stomach;
- feeling of fullness or heaviness in the epigastric region;
- dyspepsia;
- dyspepsia pregnant.
Composition
1 tablet contains:
Active substances: calcium carbonate 680 mg; magnesium carbonate basic 80 mg;
Excipients: sucrose; pregelatinized corn starch; potato starch; talc; magnesium stearate; light liquid paraffin; flavoring.
No customer reviews for the moment.
Dosage and Administration
For oral use chew or hold in mouth until completely absorbed.
Adults and children over 12 years of age (unless otherwise recommended by a doctor) when symptoms appear, 1-2 pills. If necessary, you can repeat the drug after 2 hours.
The maximum daily dose is 11 pills.
Adverse reactions
If the recommended doses are taken, the drug is well tolerated, however, in very rare cases, allergic reactions are possible - rash, angioedema, and anaphylactic reactions.
Contraindications
- hypersensitivity to the drug;
- severe renal failure;
- hypercalcemia;
- hypophosphatemia;
- nephrocalcinosis;
- children's age up to 12 years.
Drug interactions
Changes in the acidity of gastric juice during the use of antacids can lead to a decrease in the rate and extent of absorption of other drugs while taking them, so drugs should be taken 1-2 hours before or after taking antacids.
Tetracycline antibiotics, fluoroquinolones, cardiac glycosides, levothyroxine, iron preparations, fluorides, phosphates - while the use of antacids reduces the absorption of these drugs.
Thiazide diuretics - when taken concurrently with antacids, the concentration of calcium in the blood serum should be regularly monitored.
Anticholinergic drugs enhance and lengthen the action, slowing gastric emptying.
Pregnancy and Lactation
When used in recommended doses, the drug does not pose a danger to the fetus or child.
Special instructions
In the appointment of the drug to patients with impaired renal function should regularly monitor the concentration of magnesium, phosphorus and calcium in the serum.
Patients with impaired renal function is not recommended to take the drug for a long time in high doses.
Renny's application® high doses may increase the risk of kidney stones.
If the use of the drug is ineffective, you should consult your doctor for advice.
Overdosage
Symptoms: prolonged use of the drug in high doses in patients with impaired renal function can cause hypermagnemia, hypercalcemia, alkalosis, which are manifested by nausea, vomiting, muscle weakness.
Treatment: should discontinue the drug and immediately consult a doctor.
- Brand name: Rennie
- Active ingredient: Calcium carbonate, Magnesium carbonate
- Dosage form: Chewable pills
- Manufacturer: Bayer Pharma AG
- Country of Origin: Germany
Studies and clinical trials of Rennie (Click to expand)
- Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs
- Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine
- Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine
- A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine
- Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine: A Multicenter, Double-Blind, Placebo-Controlled Study Conducted in the United States
- Comparative Efficacy of Eletriptan 40 mg Versus Sumatriptan 100 mg
- Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
- Tolerability and Safety of Eletriptan in the Treatment of Migraine: A Comprehensive Review
- Efficacy of Eletriptan in Migraineurs With Persistent Poor Response to Nonsteroidal Anti-inflammatory Drugs
- Halide salts of antimigraine agents eletriptan and naratriptan
- Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity
- Quantitative analysis of eletriptan in human plasma by HPLC-MS/MS and its application to pharmacokinetic study
- Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries
- Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan
- No effect of eletriptan administration during the aura phase of migraine
- Effect of high-dose intravenous eletriptan on coronary artery diameter
- Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain – results of a model-based meta-analysis that accounts for encapsulation
- Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study
- Relvar® Ellipta® erhält europäische Marktzulassung
- Relvar Ellipta: new once-daily steroid/LABA inhaler
- Family Attitudes That Predict Home Placement of Hospitalized Psychiatric Patients
- Calcitonin gene-related peptide mediates capsaicin-induced neuroendocrine responses in rat antrum
- Role of sex in familial aggregation of blood pressure in young families
- Evidence for major genetic control of wheeze in relation to history of respiratory allergy: Humboldt family study
- Control of tumor progression by maintenance of apoptosis
- Differential transactivation by the androgen receptor in prostate cancer cells